Skip to Content
Merck
  • Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.

Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.

iScience (2024-04-29)
Chiara Montironi, Zhenghao Chen, Ingrid A M Derks, Gaspard Cretenet, Esmée A Krap, Eric Eldering, Helga Simon-Molas
ABSTRACT

The tumor suppressor p53 has been described to control various aspects of metabolic reprogramming in solid tumors, but in B cell malignancies that role is as yet unknown. We generated pairs of p53 functional and knockout (KO) clones from distinct B cell malignancies (acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B cell lymphoma, and multiple myeloma). Metabolomics and isotope tracing showed that p53 loss did not drive a common metabolic signature. Instead, cell lines segregated according to cell of origin. Next, we focused on glutamine as a crucial energy source in the B cell tumor microenvironment. In both TP53 wild-type and KO cells, glutamine deprivation induced cell death through the integrated stress response, via CHOP/ATF4. Lastly, combining BH3 mimetic drugs with glutamine starvation emerged as a possibility to target resistant clones. In conclusion, our analyses do not support a common metabolic signature of p53 deficiency in B cell malignancies and suggest therapeutic options for exploration based on glutamine dependency.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (HPLC), powder
Sigma-Aldrich
Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1), liquid, clone DO-1, Calbiochem®
Sigma-Aldrich
Oligomycin from Streptomyces diastatochromogenes, ≥90% total oligomycins basis (HPLC)
Sigma-Aldrich
Antimycin A from Streptomyces sp.
Sigma-Aldrich
Rotenone, ≥95%
Sigma-Aldrich
ISRIB, ≥98% (HPLC)